Brain Tumor, Recurrent Clinical Trial
Official title:
Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which
could revolutionize the treatment of brain tumors in children and adults. There are currently
few cases published involving the use of PDT in infratentorial (in the posterior fossa) brain
tumors in general and specifically those occurring in children. The investigators propose to
test a technique, for the first time in the U.S., that demonstrated in Australian adult
glioblastoma patients dramatic long-term, survival rates of 57% (anaplastic astrocytoma) and
37% (glioblastoma multiforme). These results are unprecedented in any other treatment
protocol.
Photodynamic therapy (PDT) is a paradigm shift in the treatment of tumors from the
traditional resection and systemic chemotherapy methods. The principle behind photodynamic
therapy is light-mediated activation of a photosensitizer that is selectively accumulated in
the target tissue, causing tumor cell destruction through singlet oxygen production.
Therefore, the photosensitizer is considered to be the first critical element in PDT
procedures, and the activation procedure is the second step. The methodology used in this
proposal utilizes more intensive laser light and larger Photofrin photosensitizer doses than
prior PDT protocols in the U.S. for brain tumor patients. The PDT will consist of
photoillumination at 630 nm beginning at the center of the tumor resection cavity, and
delivering a total energy of 240 J cm−2. The investigators feel that the light should
penetrate far enough into the tissue to reach migrating tumor cells, and destroy these cells
without harming the healthy cells in which they are dispersed.
The investigators will be testing the hypothesis that pediatric subjects with
progressive/recurrent malignant brain tumors undergoing PDT with increased doses of
Photofrin® and light energy than were used in our previous clinical study will show better
progression free survival (PFS) and overall survival (OS) outcomes. PDT will also be
effective against infratentorial tumors. The specific aims include determining the maximum
tolerable dose (MTD) of Photofrin in children and looking for preliminary effectiveness
trends.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06057168 -
Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas
|
Phase 3 | |
| Recruiting |
NCT04427384 -
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
|
||
| Completed |
NCT01967810 -
ANG1005 in Patients With Recurrent High-Grade Glioma
|
Phase 2 | |
| Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
| Completed |
NCT02303678 -
D2C7 for Adult Patients With Recurrent Malignant Glioma
|
Phase 1 | |
| Recruiting |
NCT02800486 -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
|
Phase 2 | |
| Completed |
NCT00179907 -
A Phase I/II Study of the Photon Radiosurgery System
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Withdrawn |
NCT04776980 -
Multimodality MRI and Liquid Biopsy in GBM
|
Early Phase 1 | |
| Completed |
NCT03262636 -
Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
|
Phase 1 | |
| Terminated |
NCT01966809 -
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
|
Phase 2 | |
| Completed |
NCT02458339 -
Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT03763396 -
Azoles Targeting Recurrent High Grade Gliomas
|
Early Phase 1 | |
| Active, not recruiting |
NCT04525014 -
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
Phase 1 | |
| Completed |
NCT00141765 -
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
|
Phase 2 | |
| Recruiting |
NCT05629702 -
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
|
Phase 2 | |
| Completed |
NCT02644460 -
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT01520870 -
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
|
Phase 2 | |
| Completed |
NCT02238496 -
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
|
Phase 1 | |
| Active, not recruiting |
NCT04074785 -
Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
|
Early Phase 1 |